4,5-dibromovaleric acid methyl ester | 194930-43-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 4,5-dibromovaleric acid methyl ester
• 英文别名: Methyl 4,5-dibromopentanoate；methyl 4,5-dibromopentanoate
• CAS: 194930-43-3
• 化学式: C₆H₁₀Br₂O₂
• 分子量: 273.952
• InChiKey: CNGPRKASIQMGDW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  10
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  硫代乙酸 、 4,5-dibromovaleric acid methyl ester 在 potassium hydroxide 作用下， 反应 3.0h， 生成 4,5-bis(acetylsulfanyl)valeric acid methyl ester
  参考文献：
  名称：

  Synthesis and evaluation of some novel isochroman carboxylic acid derivatives as potential anti-diabetic agents

  摘要：

  A series of novel isochroman mono-carboxylic acid derivatives were synthesized, characterized and evaluated for their ability to inhibit protein tyrosine phosphatase 1B (PTP1B) in vitro in order to use them as potential anti-diabetic agents. Analysis of structure-activity relationships led to the identification of potent compound 4n which inhibited PTP1B with IC50 value of 51.63 +/- 0.91 nM. In general, high potency was associated with a dithiolane ring with a spacer of five carbons to the isochroman ring. Compound 4n has been selected for in vivo evaluation as drug candidate for anti-diabetic activity. (C) 2009 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2009.03.009
• 作为产物：
  描述：

  甲醇 、 4,5-二溴戊酸 在 硫酸 作用下， 反应 4.0h， 生成 4,5-dibromovaleric acid methyl ester
  参考文献：
  名称：

  Synthesis and evaluation of some novel isochroman carboxylic acid derivatives as potential anti-diabetic agents

  摘要：

  A series of novel isochroman mono-carboxylic acid derivatives were synthesized, characterized and evaluated for their ability to inhibit protein tyrosine phosphatase 1B (PTP1B) in vitro in order to use them as potential anti-diabetic agents. Analysis of structure-activity relationships led to the identification of potent compound 4n which inhibited PTP1B with IC50 value of 51.63 +/- 0.91 nM. In general, high potency was associated with a dithiolane ring with a spacer of five carbons to the isochroman ring. Compound 4n has been selected for in vivo evaluation as drug candidate for anti-diabetic activity. (C) 2009 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2009.03.009

文献信息

• NON-PEPTIDIC SURROGATES OF THE ARG-GLY-ASP SEQUENCE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM
  申请人：YEDA RESEARCH AND DEVELOPMENT COMPANY, LTD.

  公开号：EP0617705A1

  公开（公告）日：1994-10-05
• EP0617705A4
  申请人：——

  公开号：EP0617705A4

  公开（公告）日：1994-12-28
• US5352667A
  申请人：——

  公开号：US5352667A

  公开（公告）日：1994-10-04
• US5519005A
  申请人：——

  公开号：US5519005A

  公开（公告）日：1996-05-21
• [EN] NON-PEPTIDIC SURROGATES OF THE ARG-GLY-ASP SEQUENCE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM
  申请人：YEDA RESEARCH AND DEVELOPMENT CO. LTD.

  公开号：WO1993009795A1

  公开（公告）日：1993-05-27

  (EN) Non-peptidic RXD analogues are provided that inhibit biological cellular and molecular interactions which are dependent on RXD recognition, wherein X is one of the amino acid residues G, E, Y, A or F. In particular, RGD surrogates are provided having no sequence of $g(a)-natural amino acids and comprising a guanidino and a carboxyl terminal groups spaced by a chain of 11 atoms, at least 5 of which are carbon atoms. The compounds inhibit cell adhesion and are useful for the treatment of several pathological disorders, e.g., thrombosis, autoimmune diseases, metastasis, allergy, host-graft reactions and inhibition of scar tissue formation.(FR) Des analogues RXD non peptidiques inhibent des interactions moléculaires et cellulaires biologiques qui dépendent de la reconnaissance de RXD, X représentant l'un des restes d'amino acides G, E, Y, A ou F. En particulier les succédanés RGD n'ont pas de séquences d'amino acides $g(a)-naturels et comprennent un groupe guanidino et un groupe terminal carboxyle espacés par une chaîne de 11 atomes, dont au moins 5 sont des atomes de carbone. Les composés empêchent l'adhésion des cellules et sont utiles pour le traitement de divers états pathologiques, par exemple, la thrombose, les maladies autoimmunes, les métastases, les allergies, les réactions hôtes-greffes et empêchent la formation de tissu cicatriciel.